The Life Science Committee
with the support of Swissnex,
Baybio,
IBMS, and
QB3
cordially invites you to join us for a:
Life Science Breakfast
"Personalized
Medicine: Changing the Face of Healthcare?"
Thursday, September 29th,
2005
7:30 am - 9:30 am
730, Montgomery Street
San Francisco
CA 94111
At Swissnex
Breakfast will be served

Swissnex connects the dots in science, education,
art and innovation,
between Switzerland and Western North America
New
understandings of disease diagnostics and treatment have fueled predictions of a
transition from "sick-care" to more integrative health care systems. Recent withdrawls of blockbuster drugs Vioxx and Tysabri
due to safety concerns highlight the dangers of a "one size fits all" drug
development model.
Taking the opposite approach, personalized
medicine seeks to
create differentiated strategies for the prevention and
care of disease through the use of 'tailored' medications. Drawing from
the convergence of pharmacogenomics and proteomics,
personalized medicine promises to make the drug development process faster,
cheaper and more
effective while
also improving drug safety.
However, this paradigm
shift also poses important ethical challenges (such as the need to balance
commercial and public health priorities) that will need to be carefully
addressed.
During our breakfast discussion panel, three Bay Area senior
executives will share their insights on the meaning and the future of the
personalized medicine revolution, to which they have directly contributed as
important actors within each of their respective companies.
Time :
7:30am to 9:30am
7:30 to 8:00
- light breakfast & networking
8:00 to 8:45
- 10 min talks by each of the 3 panelists
8:45 to 9:00
- Q&A session with the audience
|
SPEAKERS |
|
Dr. Bob Cohen,
Senior Director, Business Development, Genentech
Bob Cohen
has worked at Genentech in a variety of capacities since 1994. Bob is a
board certified hematologist/oncologist who completed his training at UCSF
before joining the faculty there in 1989. During this time he did basic
research on mechanisms of metastasis and collaborated extensively with Art
Levinson. His clinical specialty was the care of leukemia patients and
patients receiving bone marrow transplants. He is the author of over 30
scientific publications and holds 2 patents.
Bob came to
Research upon joining Genentech. In 1996 he became the project team leader
for Herceptin and led that project through Phase III completion and
registration. He also led the Genentech team that co-developed the
companion diagnostic HercepTest. In 1998 he joined Product Development
where he managed the Project Management group and the oncology team
leaders. In 2001, he rejoined Research to focus on moving late stage
research projects into Development. In 2003, he left Research to lead a
diagnostics effort in Commercial BioOncology. In 2004, Bob joined Business
Development as a senior director in the newly formed Oncology licensing
group, where he currently focuses on identifying new in-licensing
opportunities. Bob has a long history of successful work with business
development, having played important roles on both the Rituxan and Tarceva
in-licensing deals, among others.
From 1996 until 2002, Bob led a company-wide cross-functional team to
provide strategic direction for Genentech’s burgeoning oncology business.
His personal mission is to help achieve the best possible outcomes for
cancer patients. In addition to his work at Genentech, Bob has served on a
number of external scientific advisory boards, including several NIH
committees and the scientific advisory board of ABC2, a brain cancer
research and advocacy organization.
He is an avid skier, hiker, roller-blader, and is known in some Genentech
circles for his love of arcane trivia.
|
|
Dr. Thane Kreiner, Senior Vice
President, Corporate Affairs for Affymetrix, Inc.
Thane is Vice President, Corporate Affairs for Affymetrix, Inc., a leading
manufacturer of DNA microarray technology. Prior to his current position,
Dr. Kreiner held various other management positions at Affymetrix from 1994
to 2000, including Vice President, Sales and Marketing; and Vice President,
Marketing and Strategic Planning during the development of the Company's
technology and scale-up of its commercial operations. He joined the Company
full-time in April, 1994 while completing his MBA at Stanford University
Graduate School of Business.
Dr. Kreiner received his Ph.D. in Neurosciences
from Stanford University in 1988.
His undergraduate at the University of
Texas, Austin led to a B.S. in Chemistry in 1983.
|
|
Martin L. Verhoef, President of Ciphergen
Biosystems Division and an Executive Vice President of Ciphergen Biosystems,
Inc.
Martin L. Verhoef, is
President of Ciphergen’s Biosystems Division and an Executive Vice President
of Ciphergen Biosystems, Inc. Prior to joining Ciphergen, he was with
Hewlett-Packard/Agilent Technologies, Inc. from 1990 to 2000. He was
Marketing Manager, Bioscience Products from March 1999 to April 2000, System
Program Manager, Bioscience Products from September 1997 to February 1999
and Marketing Section Manager, Bioscience Products from June 1996 to August
1997. Prior to that he was Product Marketing Manager, Capillary
Electrophoresis and Liquid Chromatography from 1990 to 1996 at
Hewlett-Packard GmbH, in Waldbronn, Germany. From 1985 to 1990 he was
Product Manager, Process Chromatography at Pharmacia LKB Biotechnology AB in
Sweden. He received a BS (Hons) degree in Medical Microbiology and
Biochemistry from the Van t Hoff Institute in Rotterdam, the Netherlands. |
|
MODERATOR |
| Dr. Heather Koshinsky, CEO,
President and co-founder, Investigen, Inc.
Dr. Heather Koshinsky, CEO, President and
co-founder. Dr. Koshinsky is a microbial geneticist who previously worked at
the Plant Gene Expression Center and at the University of Saskatchewan.
She supervised microbiological/molecular biological research projects
involving yeast and bacterial genetics and food safety. Dr. Koshinsky was
also an assistant professor with University of Saskatchewan. Dr. Koshinsky
obtained a B.Sc. in Biology and a Ph.D. in Applied Microbiology from
University of Saskatchewan, and a Certificate of Business Administration
from University of California, Berkeley Extension. |
To register
|
REGISTRATION.
French American Chamber of Commerce
info@faccsf.com
Tel:
415 442 4717 / Fax: 415 442 4621
703 Market Street, Suite 450 - San Francisco, CA 94103
|
|
Registration price valid until 5-days
prior to the
event
date |
Registration is closed!
$30 At the Door
|
|
Cancellations must be
made 5-days prior to the event date
Any cancellation within
a 5-day period of the scheduled date will not be refund
Name of guest will be
kept at the door
|
Or pay using the
order form
French-American Chamber of Commerce - Life Science
Breakfast:
Thursday, September 29th 2005, 7:30 am - 9:30 am
I wish to reserve ___ tickets at $20 for FACCSF
members and affiliated only
___ tickets at $25 for non
members
Name
_________________________________________________________________________
Company_______________________________________________________________________
Address________________________________________________________________________
City________________________________________State___________Zip__________________
Email
address___________________________________________________________________
Phone
______________________________________Fax________________________________
Visa/MC
Number_________________________________________________________________
Exp. Date___________________________________
Signature____________________________
Please, fax this
coupon to:
French-American Chamber of Commerce
703 Market Street, Suite 450, San
Francisco, CA 94103
Tel: 415 442 4717 / Fax 415 442 4621